Our long-term goal is to treat glaucoma using systemic neuroprotective gene therapy. Nearly 3 million people have been diagnosed with glaucoma, a leading cause of blindness in the United States. Current therapies are directed at lowering the intraocular pressure (IOP), the most significant risk factor for the development of glaucoma. The need for daily treatment can lead to poor patient compliance. We offer an alternative IOP-independent neuroprotective therapy, a modified form of erythropoietin (EPO). EPO is already FDA approved for the treatment of anemia. We modified EPO to diminish the erythropoietic activity while preserving its neuroprotective activity, and packaged it into an adeno-associated viral vector (rAAV) to provide sustained, systemic delivery. Transduction of peripheral muscle by a single injection protects 70% of RGC somata and axons, and preserves visual function in the DBA/2J mouse. We have preliminary data that treatment with our novel gene therapy vector, rAAV.EpoR76E, decreases levels of C1Q and glial fibrillary acidic protein in the retina of 10 month old DBA/2J mice. There is also evidence that EPO can decrease the levels of Aquaporin 4 (AQP4), a water channel that induces astrocyte hypertrophy in the brain. Further, we have preliminary data that all of these proteins interact based on correlation analysis of microarray data. The proposed study will test two conceptual hypotheses. Our first conceptual hypothesis is that EPO-R76E, blocks astrocyte hypertrophy and the resulting mechanical injury to the axons and secondary RGC death by downregulation of the water channel, AQP4. Our second conceptual hypothesis predicts that synapse targeting by the immune system initiates the cascade of RGC death in glaucoma. We propose that treatment with rAAV.EpoR76E blocks synapse targeting by C1Q, thus preserving normal synaptic connections and visual function. These hypotheses will be tested in the DBA/2J, and additional novel mouse models of glaucoma.

Public Health Relevance

We developed a novel gene therapy treatment for glaucoma that is intraocular pressure (IOP)-independent, protects 70% of RGC somata and axons, and preserves visual function in the DBA/2J mouse. We will test this therapy in novel mouse models of glaucoma. We will also test two hypotheses on the mechanism of action of our therapeutic, a modified form of erythropoietin, EPO-R76E: 1) EPO-R76E blocks astrocyte hypertrophy and the resulting mechanical injury to the axons by downregulation of the water channel, Aquaporin 4;and 2) EPO-R76E blocks synapse targeting by C1Q, thus preserving normal synaptic connections and visual function.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY022349-04
Application #
8655887
Study Section
Anterior Eye Disease Study Section (AED)
Program Officer
Chin, Hemin R
Project Start
2012-04-01
Project End
2017-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
City
Nashville
State
TN
Country
United States
Zip Code
37212
Guley, Natalie H; Rogers, Joshua T; Del Mar, Nobel A et al. (2016) A Novel Closed-Head Model of Mild Traumatic Brain Injury Using Focal Primary Overpressure Blast to the Cranium in Mice. J Neurotrauma 33:403-22
Bond, Wesley S; Hines-Beard, Jessica; GoldenMerry, Y Paul L et al. (2016) Virus-mediated EpoR76E Therapy Slows Optic Nerve Axonopathy in Experimental Glaucoma. Mol Ther 24:230-9
Hines-Beard, Jessica; Bond, Wesley S; Backstrom, Jon R et al. (2016) Virus-mediated EpoR76E gene therapy preserves vision in a glaucoma model by modulating neuroinflammation and decreasing oxidative stress. J Neuroinflammation 13:39
Rex, Tonia S; Boyd, Kelli; Apple, Troy et al. (2016) Effects of Repeated Anesthesia Containing Urethane on Tumor Formation and Health Scores in Male C57BL/6J Mice. J Am Assoc Lab Anim Sci 55:295-9
Bricker-Anthony, Courtney; Rex, Tonia S (2015) Neurodegeneration and Vision Loss after Mild Blunt Trauma in the C57Bl/6 and DBA/2J Mouse. PLoS One 10:e0131921
Rex, Tonia S; Reilly, Matthew A; Sponsel, William Eric (2015) Elucidating the effects of primary blast on the eye. Clin Exp Ophthalmol 43:197-9
de Lucas Cerrillo, A M; Bond, W S; Rex, T S (2015) Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin. Gene Ther 22:365-73
Bricker-Anthony, Courtney; Hines-Beard, Jessica; D'Surney, Lauren et al. (2014) Exacerbation of blast-induced ocular trauma by an immune response. J Neuroinflammation 11:192
Bricker-Anthony, Courtney; Hines-Beard, Jessica; Rex, Tonia S (2014) Molecular changes and vision loss in a mouse model of closed-globe blast trauma. Invest Ophthalmol Vis Sci 55:4853-62
Bond, Wesley S; Rex, Tonia S (2014) Evidence That Erythropoietin Modulates Neuroinflammation through Differential Action on Neurons, Astrocytes, and Microglia. Front Immunol 5:523

Showing the most recent 10 out of 14 publications